SCHEMBL30839554

SCHEMBL30839554

NC(=O)c1ccccc1Cc1cscn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.40
PKM P14618 1/20 0.40
SLC6A3 Q01959 3/20 0.38
PARP1 P09874 2/20 0.38
MAPT P10636 3/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GPR142 Q7Z601 1/20 0.36
SYK P43405 1/20 0.35
METAP2 P50579 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
GAA P10253 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
BCAT2 O15382 1/20 0.34
CSNK1A1 P48729 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30952658 0.83 KDM4C (0.45) KDM4CPKMSLC6A3PARP1GPR142
SCHEMBL31659925 0.79 PARP1 (0.42) KDM4CPKMPARP1MAPTKDM4E
SCHEMBL29818128 0.76 PARP10 (0.48) PARP1KDM4EALDH1A1HPGDTSHR
SCHEMBL166483 0.76 PARP10 (0.48) PARP1KDM4EALDH1A1HPGDTSHR
SCHEMBL7134588 0.76 TSHR (0.54) PARP1MAPTKDM4EALDH1A1HPGD
SCHEMBL11065012 0.76 MAPT (0.45) SLC6A3MAPTKDM4ETSHRMETAP2
SCHEMBL28213057 0.73 TSHR (0.42) PARP1MAPTKDM4EALDH1A1HPGD
SCHEMBL12484782 0.73 P2RX7 (0.38) PARP1MAPTKDM4EALDH1A1HPGD
SCHEMBL4759339 0.73 PARP1 (0.39) PARP1MAPTKDM4EALDH1A1HPGD
SCHEMBL25389649 0.72 TSHR (0.41) PARP1MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240082223-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240082223-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA KDM4C 1397/4885PKM 1030/4885SLC6A3 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.